Perspective Therapeutics (NYSE:CATX) Upgraded at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Perspective Therapeutics (NYSE:CATX) to a strong-buy rating in a report issued on Tuesday morning,Zacks.com reports. Cantor Fitzgerald also issued estimates for Perspective Therapeutics’ FY2024 earnings at ($0.90) EPS and FY2025 earnings at ($1.09) EPS.

Other research analysts have also issued research reports about the company. Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $24.00 to $5.00 in a research report on Monday, November 25th. Royal Bank of Canada restated an “outperform” rating and set a $16.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Oppenheimer cut their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, November 22nd. Finally, Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Friday, January 24th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Perspective Therapeutics currently has an average rating of “Buy” and a consensus price target of $15.14.

Perspective Therapeutics Price Performance

NYSE:CATX opened at $2.70 on Tuesday. The business’s 50-day simple moving average is $3.22 and its two-hundred day simple moving average is $7.84. Perspective Therapeutics has a 52 week low of $2.32 and a 52 week high of $19.05.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC grew its position in Perspective Therapeutics by 3,994.9% in the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after acquiring an additional 5,370,392 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Perspective Therapeutics by 8.0% during the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after buying an additional 355,685 shares during the period. Deerfield Management Company L.P. Series C boosted its position in shares of Perspective Therapeutics by 4.3% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company’s stock valued at $9,375,000 after buying an additional 120,991 shares during the period. Octagon Capital Advisors LP boosted its position in shares of Perspective Therapeutics by 62.1% during the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock valued at $7,352,000 after buying an additional 882,528 shares during the period. Finally, State Street Corp boosted its position in shares of Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after buying an additional 1,192,812 shares during the period. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.